Carolina Fonseca de Barros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carolina Fonseca de Barros has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Adelson Héric Alves Monteiro
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
2 shared publications - Amanda de Almeida Silva
Department of Cardiopneumology, Heart Institute, Faculty of Medicine University of Sao Paulo Sao Paulo Brazil
2 shared publications - Amanda de Sá Martins de Bessa
INCT-Nanobiofar, Department of Physiology and Biophysics (R.A.S.S., A.S.M.B., C.F.B., M.F.I., F.A.S., S.C.A.G., L.R.-R., K.S.F., S.S., I.Z.L.F.F., U.F.V.-M., A.C.V.G., A.H.A.M., M.E., B.S., A.M., G.M., N.P.S., D.A.A.P., J.R.R., M.L.D.-P., D.M.-S., M.A.P.F., A.S.H., T.V.-B., S.G., M.F.L., M.J.C.-S.), Federal University of Minas Gerais (UFMG), Brazil
2 shared publications - Ana Caroline Ventris de Godoy
INCT-Nanobiofar, Department of Physiology and Biophysics (R.A.S.S., A.S.M.B., C.F.B., M.F.I., F.A.S., S.C.A.G., L.R.-R., K.S.F., S.S., I.Z.L.F.F., U.F.V.-M., A.C.V.G., A.H.A.M., M.E., B.S., A.M., G.M., N.P.S., D.A.A.P., J.R.R., M.L.D.-P., D.M.-S., M.A.P.F., A.S.H., T.V.-B., S.G., M.F.L., M.J.C.-S.), Federal University of Minas Gerais (UFMG), Brazil
2 shared publications - Ana Cristina Simoes-E-Silva
Department of Pediatrics, Unit of Pediatric Nephrology, Interdisciplinary Laboratory of Medical Investigation, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil
2 shared publications - Ana Paula Davel
Universidade Estadual de Campinas
2 shared publications
Latest Publications
- Top Cited Papers
- 2 January 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (1)
Identification and Characterization of Alamandine-(1-5), a New Component of the Renin-Angiotensin System
BACKGROUND: The renin-angiotensin system comprises a biochemical cascade that hydrolyzes angiotensinogen into several different bioactive peptides, which can activate different receptors, promoting plenty of specific effects. This study aimed to evaluate the presence of the putative product of alamandine, the pentapeptide Ala-(1-5) (alamandine-[1-5]), in the circulation and its biological activity. METHODS: To accomplish this, we have used mass spectrometry (Matrix-assisted Laser Desorption/Ionization Time-of-Flight/Time-of-Flight mass spectrometry [MALDI/TOF/TOF], Liquid Chromatography-Tandem Mass Spectrometry [LC-MS/MS]) and several methodologies, including isolated blood vessels, isolated perfused hearts, isolated cardiomyocytes, blood pressure recording in freely moving normotensive and spontaneously hypertensive rats, high-resolution echocardiography, central administration (intracerebroventricular infusion and microinjection in the insular cortex), cell culture (endothelial cells and G-protein–coupled receptors-transfected Chinese Hamster Ovary cells), and wild-type and Mas (Mas receptor proto-oncogene), MrgD (Mas-related G-protein–coupled receptor subtype D), or AT2 (angiotensin II type 2) receptor-deficient mice. RESULTS: We show that Ala-(1-5) is present in the circulation of healthy humans and rodents and promotes many biological central and peripheral actions. A major role for ACE (angiotensin-converting enzyme) activity in the formation of Ala-(1-5) from alamandine in the circulation was observed using plasma samples from angiotensinogen-knockout mice. Ala-(1-5) increases baroreflex sensitivity and produces a long-lasting (≈6 hours) antihypertensive effect in spontaneously hypertensive rats, associated with a significant reduction in cardiac output. Additionally, Ala-(1-5) decreases inotropism in isolated perfused hearts and reduces contractility in cardiomyocytes. In Chinese Hamster Ovary cells-transfected cells, Ala-(1-5) can bind and stimulate NO production through all receptors from the renin-angiotensin system protective arm (Mas, MrgD, and AT 2 receptors). On the other hand, the Ala-(1-5) effects on cardiomyocytes and mouse aortic rings were abolished only by MrgD genetic deletion, but not by Mas or AT2 receptor knockout. CONCLUSIONS: Our data demonstrate that Ala-(1-5) is a newly identified peptide within the renin-angiotensin system, with strong blood pressure–lowering effects that vary in mechanisms of action among different tissues. Ala-(1-5) has distinct characteristics that differentiate it from the conventional renin-angiotensin system pathways responsible for reducing blood pressure.
- 2 January 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (1)
Top Cited PapersIdentification and Characterization of Alamandine-(1-5), a New Component of the Renin-Angiotensin System
BACKGROUND: The renin-angiotensin system comprises a biochemical cascade that hydrolyzes angiotensinogen into several different bioactive peptides, which can activate different receptors, promoting plenty of specific effects. This study aimed to evaluate the presence of the putative product of alamandine, the pentapeptide Ala-(1-5) (alamandine-[1-5]), in the circulation and its biological activity. METHODS: To accomplish this, we have used mass spectrometry (Matrix-assisted Laser Desorption/Ionization Time-of-Flight/Time-of-Flight mass spectrometry [MALDI/TOF/TOF], Liquid Chromatography-Tandem Mass Spectrometry [LC-MS/MS]) and several methodologies, including isolated blood vessels, isolated perfused hearts, isolated cardiomyocytes, blood pressure recording in freely moving normotensive and spontaneously hypertensive rats, high-resolution echocardiography, central administration (intracerebroventricular infusion and microinjection in the insular cortex), cell culture (endothelial cells and G-protein–coupled receptors-transfected Chinese Hamster Ovary cells), and wild-type and Mas (Mas receptor proto-oncogene), MrgD (Mas-related G-protein–coupled receptor subtype D), or AT2 (angiotensin II type 2) receptor-deficient mice. RESULTS: We show that Ala-(1-5) is present in the circulation of healthy humans and rodents and promotes many biological central and peripheral actions. A major role for ACE (angiotensin-converting enzyme) activity in the formation of Ala-(1-5) from alamandine in the circulation was observed using plasma samples from angiotensinogen-knockout mice. Ala-(1-5) increases baroreflex sensitivity and produces a long-lasting (≈6 hours) antihypertensive effect in spontaneously hypertensive rats, associated with a significant reduction in cardiac output. Additionally, Ala-(1-5) decreases inotropism in isolated perfused hearts and reduces contractility in cardiomyocytes. In Chinese Hamster Ovary cells-transfected cells, Ala-(1-5) can bind and stimulate NO production through all receptors from the renin-angiotensin system protective arm (Mas, MrgD, and AT 2 receptors). On the other hand, the Ala-(1-5) effects on cardiomyocytes and mouse aortic rings were abolished only by MrgD genetic deletion, but not by Mas or AT2 receptor knockout. CONCLUSIONS: Our data demonstrate that Ala-(1-5) is a newly identified peptide within the renin-angiotensin system, with strong blood pressure–lowering effects that vary in mechanisms of action among different tissues. Ala-(1-5) has distinct characteristics that differentiate it from the conventional renin-angiotensin system pathways responsible for reducing blood pressure.
- Open Access
Identification and characterization of alamandine-(1-5), a new component of the Renin-Angiotensin System with unique properties
The renin-angiotensin system (RAS) comprises a biochemical cascade that hydrolyzes angiotensinogen into several different bioactive peptides, which can activate different receptors promoting plenty of specific effects. The aim of this study was to evaluate the presence of the putative product of alamandine, the pentapeptide alamandine-(1-5) in the circulation and its biological activity. To accomplish this we have used mass spectrometry (MALDI/TOF/TOF, LC-MS/MS) and several methodologies including isolated blood vessels, isolated perfused hearts, isolated cardiomyocytes, blood pressure recording in freely-moving normotensive and hypertensive rats (SHR), high resolution echocardiography (VEVO 2100), central administration (ICV infusion and microinjection in the insular cortex), cell culture (endothelial cells and GPCR-transfected CHO cells) and wild type and Mas, MrgD or AT2R deficient mice. Our results show that alamandine-(1-5) circulates in the human and rodent blood and promotes many biological central and peripheral actions. More importantly, its plasma concentration is increased in pediatric nephropathic patients. A major role for plasma ACE activity in the formation of alamandine-(1-5) from alamandine was observed using plasma samples from Angiotensinogen-KO mice. Alamandine-(1-5) increased Baroreflex sensitivity and produced a long-lasting (∼6 hours) anti-hypertensive effect in SHR, associated with a significant reduction in cardiac output. A particularly important effect of this pentapeptide was observed in isolated perfused heart and cardiomyocyte contractility (reduced inotropism). It was capable of stimulating NO production through all receptors from the renin-angiotensin protective arm, (MAS, MrgD and AT2R) in CHO-transfected cells. Our data shows that Alamandine-(1-5) exhibits selective actions that set it apart from traditional concepts of the vasodilatory axis of the RAS and that are possibly intricately linked to a complex interplay between Mas, MrgD and AT2 receptors. This novel finding suggests that RAS may possess a complexity that surpasses our current understanding.
Open AccessIdentification and characterization of alamandine-(1-5), a new component of the Renin-Angiotensin System with unique properties
The renin-angiotensin system (RAS) comprises a biochemical cascade that hydrolyzes angiotensinogen into several different bioactive peptides, which can activate different receptors promoting plenty of specific effects. The aim of this study was to evaluate the presence of the putative product of alamandine, the pentapeptide alamandine-(1-5) in the circulation and its biological activity. To accomplish this we have used mass spectrometry (MALDI/TOF/TOF, LC-MS/MS) and several methodologies including isolated blood vessels, isolated perfused hearts, isolated cardiomyocytes, blood pressure recording in freely-moving normotensive and hypertensive rats (SHR), high resolution echocardiography (VEVO 2100), central administration (ICV infusion and microinjection in the insular cortex), cell culture (endothelial cells and GPCR-transfected CHO cells) and wild type and Mas, MrgD or AT2R deficient mice. Our results show that alamandine-(1-5) circulates in the human and rodent blood and promotes many biological central and peripheral actions. More importantly, its plasma concentration is increased in pediatric nephropathic patients. A major role for plasma ACE activity in the formation of alamandine-(1-5) from alamandine was observed using plasma samples from Angiotensinogen-KO mice. Alamandine-(1-5) increased Baroreflex sensitivity and produced a long-lasting (∼6 hours) anti-hypertensive effect in SHR, associated with a significant reduction in cardiac output. A particularly important effect of this pentapeptide was observed in isolated perfused heart and cardiomyocyte contractility (reduced inotropism). It was capable of stimulating NO production through all receptors from the renin-angiotensin protective arm, (MAS, MrgD and AT2R) in CHO-transfected cells. Our data shows that Alamandine-(1-5) exhibits selective actions that set it apart from traditional concepts of the vasodilatory axis of the RAS and that are possibly intricately linked to a complex interplay between Mas, MrgD and AT2 receptors. This novel finding suggests that RAS may possess a complexity that surpasses our current understanding.
- Open Access
- 7 August 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (9) , e655997433
Blood pressure decrease in elderly after isometric training: does lactate play a role?
This study aimed to investigate the effect of isometric handgrip (IHG) training on the blood pressure (BP) reduction in prehypertensive and hypertensive elderly people, and the possible role of lactate and redox balance. Thirty-three older (75.3±1.3 years old) were allocated to a non-exercise control (CG, n=11), prehypertensive (PHG, n=10), and hypertensive (HG, n=12) groups. PHG and HG performed a total of 8 sets of 1-min bilateral contractions at 30% maximal voluntary isometric contraction, each separated by 1-minute rest-pause. IHG training was performed for 8-week, 3 times a week on non-consecutive days. Systolic BP (SBP) and heart rate (HR) decreased post-training on PHG (-10 mm Hg; -5 bpm) and HG (-16 mm Hg; -9 bpm), respectively. Diastolic BP (DBP) decreased for HG only (-9 mm Hg) (P < 0.05). In addition, the decrease in BP occurred in parallel to a better redox balance and increased bioavailability of nitric oxide in PHG and HG (P < 0.05). Also, the variables that most present association to SBP decrease were capillary blood lactate concentration and muscle strength (P < 0.05). In summary, IHG training may be practical in improving clinical status of prehypertensive and hypertensive patients, by improving BP control, NO- bioavailability and redox balance. Further studies are required to elucidate the pathways of lactate concentration in blood-flow during exercise.
- 7 August 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (9) , e655997433
Open AccessBlood pressure decrease in elderly after isometric training: does lactate play a role?
This study aimed to investigate the effect of isometric handgrip (IHG) training on the blood pressure (BP) reduction in prehypertensive and hypertensive elderly people, and the possible role of lactate and redox balance. Thirty-three older (75.3±1.3 years old) were allocated to a non-exercise control (CG, n=11), prehypertensive (PHG, n=10), and hypertensive (HG, n=12) groups. PHG and HG performed a total of 8 sets of 1-min bilateral contractions at 30% maximal voluntary isometric contraction, each separated by 1-minute rest-pause. IHG training was performed for 8-week, 3 times a week on non-consecutive days. Systolic BP (SBP) and heart rate (HR) decreased post-training on PHG (-10 mm Hg; -5 bpm) and HG (-16 mm Hg; -9 bpm), respectively. Diastolic BP (DBP) decreased for HG only (-9 mm Hg) (P < 0.05). In addition, the decrease in BP occurred in parallel to a better redox balance and increased bioavailability of nitric oxide in PHG and HG (P < 0.05). Also, the variables that most present association to SBP decrease were capillary blood lactate concentration and muscle strength (P < 0.05). In summary, IHG training may be practical in improving clinical status of prehypertensive and hypertensive patients, by improving BP control, NO- bioavailability and redox balance. Further studies are required to elucidate the pathways of lactate concentration in blood-flow during exercise.